{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    7,
    20,
    25,
    26,
    34,
    41,
    45,
    47,
    48,
    49,
    50,
    52,
    54
  ],
  "modelUsed": "gpt-5.1",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Screening procedures clarified in Section 8",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities (SoA), Table 1",
        "description": "Amendment summary states that a footnote in the Schedule of Activities table is updated to state that procedures specific to screening sites (US only) are detailed in Section 8."
      },
      {
        "id": "ref_2",
        "name": "US-specific screening sites detail",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8",
        "sectionTitle": "Study Assessments and Procedures",
        "description": "Amendment summary notes that Section 8 adds text applicable only to the US detailing the possibility for sites to perform only screening procedures and not remaining study procedures."
      },
      {
        "id": "ref_3",
        "name": "COVID-19 vaccine risk assessment",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2.3.1.1",
        "sectionTitle": "Coronavirus (SARS-CoV-2) Disease 2019",
        "description": "Text notes that specific consideration has been given to potential risks and mitigation measures due to the COVID-19 vaccine and directs the reader to Section 10.5."
      },
      {
        "id": "ref_4",
        "name": "Dose modification reference in risk table",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2.3.1",
        "sectionTitle": "Risk Assessment",
        "description": "Within Table 3, the mitigation strategy for several risks includes dose modification or discontinuation with a reference to Section 6.6 for details of dose modification criteria."
      },
      {
        "id": "ref_5",
        "name": "Outpatient period extension limits",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.1",
        "sectionTitle": "Overall Design",
        "description": "Text describing adaptive design indicates that adaptive features and their limits are detailed in Table 4."
      },
      {
        "id": "ref_6",
        "name": "Dose modification criteria linkage",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.1",
        "sectionTitle": "Overall Design",
        "description": "Adaptive feature 4 in Table 4 refers to relevant Dose Modification criteria defined in Table 7."
      },
      {
        "id": "ref_7",
        "name": "Blood donation exclusion cross-reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.3",
        "sectionTitle": "Lifestyle Considerations",
        "description": "In the lifestyle restriction table, the restriction on blood and plasma donation refers to an exclusion criterion defined in Section 5.2."
      },
      {
        "id": "ref_8",
        "name": "Contraception cross-reference from lifestyle considerations",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.3",
        "sectionTitle": "Lifestyle Considerations",
        "description": "Contraception requirements reference appropriate contraceptive methods described in Section 10.4 and start times for contraceptives according to methods described in Section 5.1."
      },
      {
        "id": "ref_9",
        "name": "Schedule of Activities for study intervention discontinuation",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.1",
        "sectionTitle": "Discontinuation of Study Intervention",
        "description": "Directs readers to the Schedule of Activities in Section 1.3 for data to be collected at the time of discontinuation of study intervention and follow-up."
      },
      {
        "id": "ref_10",
        "name": "Dose modification criteria for abnormal liver function",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.1",
        "sectionTitle": "Discontinuation of Study Intervention",
        "description": "States that discontinuation of study intervention for abnormal liver function should be considered when conditions outlined in the Dose Modification criteria in Section 6.6 are met."
      },
      {
        "id": "ref_11",
        "name": "Pregnancy discontinuation criteria",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.1",
        "sectionTitle": "Discontinuation of Study Intervention",
        "description": "Lists pregnancy or planned pregnancy as a reason for discontinuation and cross-refers to Section 8.2.6 for pregnancy details."
      },
      {
        "id": "ref_12",
        "name": "Table 1 reference for discontinuation visit procedures",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.1",
        "sectionTitle": "Discontinuation of Study Intervention",
        "description": "Instructs to see the Schedule of Activities (Table 1) for samples and data to be collected at the time of study intervention discontinuation and follow-up."
      },
      {
        "id": "ref_13",
        "name": "Schedule of Activities for early discontinuation",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.2",
        "sectionTitle": "Participant Discontinuation/Withdrawal From the Study",
        "description": "Indicates that an early discontinuation visit should be conducted as shown in the Schedule of Activities and that Section 1.3 should be consulted for data to be collected at study discontinuation and follow-up."
      },
      {
        "id": "ref_14",
        "name": "ECG withdrawal criteria linkage",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.3",
        "sectionTitle": "Electrocardiograms",
        "description": "Specifies that triplicate ECGs will be conducted as outlined in the SoA (Section 1.3) and refers to Section 7 for QTc withdrawal criteria and any additional QTc readings."
      },
      {
        "id": "ref_15",
        "name": "Clinical laboratory test list and timing",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.4",
        "sectionTitle": "Clinical Safety Laboratory Assessments",
        "description": "Directs the reader to Section 10.2 for the list of clinical laboratory tests and to the SoA (Section 1.3) for timing and frequency of assessments."
      },
      {
        "id": "ref_16",
        "name": "Protocol-required laboratory assessments definition",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.4",
        "sectionTitle": "Clinical Safety Laboratory Assessments",
        "description": "States that all protocol-required laboratory assessments, as defined in Section 10.2, must be conducted according to the laboratory manual and the SoA."
      },
      {
        "id": "ref_17",
        "name": "AE/SAE linkage to discontinuation section",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.3",
        "sectionTitle": "Adverse Events and Serious Adverse Events",
        "description": "Notes that investigators remain responsible for following up AEs that caused the participant to discontinue the study intervention, with a cross-reference to Section 7 for discontinuation details."
      },
      {
        "id": "ref_18",
        "name": "Procedures for AE and SAE handling",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.3",
        "sectionTitle": "Adverse Events and Serious Adverse Events",
        "description": "States that procedures for recording, evaluating, follow-up, and reporting AEs and SAEs are outlined in Section 10.3."
      },
      {
        "id": "ref_19",
        "name": "SAE reporting timelines cross-reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.3.1",
        "sectionTitle": "Time Period and Frequency for Collecting AE and SAE Information",
        "description": "Indicates that all SAEs must be recorded and reported as indicated in Section 10.3."
      },
      {
        "id": "ref_20",
        "name": "AE/SAE detection and reporting methods",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.3.2",
        "sectionTitle": "Method of Detecting AEs and SAEs",
        "description": "Specifies that methods for recording, evaluating, assessing causality, and completing and transmitting SAE reports are provided in Section 10.3."
      },
      {
        "id": "ref_21",
        "name": "Lost to follow-up definition",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.3.3",
        "sectionTitle": "Follow-up of AEs and SAEs",
        "description": "States that SAEs will be followed until resolution, stabilization, explanation, or participant is lost to follow-up as defined in Section 7.3."
      },
      {
        "id": "ref_22",
        "name": "Biobanked sample genetic testing exclusion",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.3.6",
        "sectionTitle": "Retained and Biobanked Sample",
        "description": "Clarifies that the retained biobanked sample will not be used for genetic testing and refers to Section 8.7 for genetics."
      },
      {
        "id": "ref_23",
        "name": "PK sampling schedule",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.5",
        "sectionTitle": "Pharmacokinetics",
        "description": "Specifies that whole blood samples for molybdenum measurements will be collected as specified in the SoA (Table 1)."
      },
      {
        "id": "ref_24",
        "name": "Copper balance measurements cross-reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.5",
        "sectionTitle": "Pharmacokinetics",
        "description": "Directs readers to Section 8.1.1 for details of molybdenum measured in food, drinks, urine, and feces."
      },
      {
        "id": "ref_25",
        "name": "PD sampling schedule",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.6",
        "sectionTitle": "Pharmacodynamics",
        "description": "States that blood samples for PD endpoints will be collected as described in the SoA (Table 1) for plasma isolation."
      },
      {
        "id": "ref_26",
        "name": "Copper and biomarker measurement details",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.8",
        "sectionTitle": "Biomarkers",
        "description": "Refers readers to Section 8.6 for details of plasma copper-related biomarkers and to Section 8.1.1 for details of copper measured in food, drink, urine, and feces."
      },
      {
        "id": "ref_27",
        "name": "Populations for analysis table",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.3",
        "sectionTitle": "Populations for Analyses",
        "description": "Indicates that the population sets used for analysis are defined in Table 8."
      },
      {
        "id": "ref_28",
        "name": "Use of PK/PD Analysis Set",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.4.4",
        "sectionTitle": "Pharmacokinetic, Pharmacodynamic, and Biomarker Analyses",
        "description": "States that analyses for PK, PD, and biomarker endpoints will be performed using the PK/PD Analysis Set described in Table 8."
      },
      {
        "id": "ref_29",
        "name": "ECG analysis and SoA linkage",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.4.3",
        "sectionTitle": "Safety Analyses",
        "description": "Indicates that electrocardiogram parameters will be measured at specified time points as per the SoA (Table 1)."
      },
      {
        "id": "ref_30",
        "name": "IRB/IEC safety notifications",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.3.4",
        "sectionTitle": "Regulatory Reporting Requirements for SAEs",
        "description": "States that an Investigator who receives an Investigator safety report describing an SAE or other safety information from Alexion will file it with the IB and notify the IRB/IEC according to local requirements."
      },
      {
        "id": "ref_31",
        "name": "Risk rationale referencing IB",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2.3.1",
        "sectionTitle": "Risk Assessment",
        "description": "Within Table 3, several risk rationales cite results obtained from studies of ALXN1840 and ammonium tetrathiomolybdate in participants with Wilson disease and instruct the reader to see the Investigator’s Brochure (IB)."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; IB = Investigator’s Brochure; PK = pharmacokinetics; WD = Wilson disease.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "2.3.1 Risk Assessment / Table 3: Potential Risks and Mitigation Strategy",
        "pageNumber": 21
      },
      {
        "id": "annot_2",
        "text": "Abbreviations: CRF = case report form; CRU = clinical research unit; EOS = End of Study; SoA = Schedule of Activities.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "5.3 Lifestyle Considerations",
        "pageNumber": 35
      },
      {
        "id": "annot_3",
        "text": "Abbreviations: ICF = informed consent form; PD = pharmacodynamic; PK = pharmacokinetic.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.3 Populations for Analyses / Table 8: Populations for Analysis",
        "pageNumber": 51
      },
      {
        "id": "annot_4",
        "text": "Note: total molybdenum and PUF molybdenum concentration-time profiles on Day 28 after the last 15 mg ALXN1840 dose will be extrapolated to Day 29 (0-24 hr) and subtracted from the observed Day 29 concentration-time profiles after the first 30 mg ALXN1840 dose in order to determine the actual accumulation for the 30 mg dose level.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.4.4 Pharmacokinetic, Pharmacodynamic, and Biomarker Analyses",
        "pageNumber": 53
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "Amendment 3.1 (US)",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2022-03-18",
        "description": "Substantial protocol amendment clarifying study procedures for US sites to facilitate participant recruitment and reduce inconvenience without compromising study quality.",
        "amendmentNumber": "3.1 (US)"
      },
      {
        "id": "ver_2",
        "versionNumber": "Original Protocol",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-05-12",
        "description": "Initial version of protocol ALXN1840-WD-204 for the Phase 2 open-label study of ALXN1840 in Wilson disease."
      },
      {
        "id": "ver_3",
        "versionNumber": "Amendment 1",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-08-18",
        "description": "First protocol amendment; specific content not detailed in provided extract.",
        "amendmentNumber": "1"
      },
      {
        "id": "ver_4",
        "versionNumber": "Amendment 2",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-03-19",
        "description": "Second protocol amendment; specific content not detailed in provided extract.",
        "amendmentNumber": "2"
      },
      {
        "id": "ver_5",
        "versionNumber": "Amendment 3",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-08-31",
        "description": "Third protocol amendment; specific content not detailed in provided extract.",
        "amendmentNumber": "3"
      }
    ],
    "summary": {
      "referenceCount": 31,
      "annotationCount": 4,
      "versionCount": 5
    }
  }
}